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Invasive aspergillosis represents a clinical picture frequently associated with host’s immunosuppression which usually involves a
high morbidity and mortality. In general, the most frequent fungal entry is the lungs with secondary hematogenous
dissemination, but there are other hypotheses like a gastrointestinal portal of entry. There are some rare publications of cases
with invasive aspergillosis in immunocompetent patients. We present the case of an immunocompetent patient without any risk
factors except for age, ICU stay, and surgical intervention, who developed a septic shock by invasive gastrointestinal aspergillosis
as primary infection. Due to the unusualness of the case, despite all the measures taken, the results were obtained postmortem.
We want to emphasize the need not to underestimate the possibility for an invasive aspergillosis in an immunocompetent
patient. Not only pulmonary but also gastrointestinal aspergillosis should be taken into account in the differential diagnosis to
avoid a delay of treatment.
1. Introduction
Aspergillus represents a group of fungi with a ubiquitous dis-
tribution, whose spores (conidia) are easily transported
through the air, as most important transmission route.
Within the group of aspergillus, A. fumigatus represents
more than 80% of severe human aspergillus infections [1].
The most frequent human infection is invasive pulmonary
aspergillosis, followed by infections of nasal sinuses, the cen-
tral nervous system, and, rarely, gastrointestinal infections.
Ingested spores cannot penetrate an intact mucosal barrier,
but pathology of the mucosal barrier is needed to cause an
invasive gastrointestinal aspergillosis [2, 3].
Patients affected by aspergillus are generally immuno-
compromised, with chronic use of corticosteroids or immu-
nosuppressive treatments, prolonged neutropenia, hepatic
cirrhosis, chronic granulomatous diseases, or a human
immunodeficiency virus infection. Diabetics with hypergly-
cemia also have an impaired immune response, which per-
mits bacterial or fungal colonization and sometimes
invasion through the skin or mucosa [1, 4]. It is believed that
these patients show an impaired immune response in mono-
nuclear phagocytic function, leading to a dysfunction of alve-
olar macrophages [5]. An invasive aspergillosis in these
patients presents as a severe illness with an unfavorable prog-
nosis. We are reporting a rare case of an invasive gastrointes-
tinal aspergillosis in an immunocompetent patient without
any risk factors. The outcome in this case is equally bad
and illustrates why early recognition and intervention is cru-
cial for the prognosis.
2. Case Presentation
In the year 2019, an 88-year-old, autonomous female with a
past medical history of hyperparathyroidism, dyslipidemia,
and nonrelevant cardiopathy (treatment with aspirin, meto-
prolol, and atorvastatin) presents in the emergency room
with vomiting and diarrhea after eating fish the day before.
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For months, she suffered from diffuse abdominal pain, for
which she medicated herself with paracetamol and metami-
zole. At the first examination, the patient was in a good gen-
eral condition but showed an erythematous and painful left
arm. The blood test showed leukocytosis (7.3G/l) with left
deviation and C-reactive protein (CRP) of 175mg/l. An anti-
biotic therapy with ceftriaxone intravenous was begun, and
an outpatient treatment was started with daily consultation
for medication administration. At the second consultation,
the patient showed a deterioration of general state, with
disorientation, slowing down, and tendency to hypotension.
The left arm showed an aggravation with swelling, livid
discoloration of the skin, compatible with erysipelas. The
abdomen was distended, painful, without peristalsis. A
reexamination of the blood indicated an acute renal failure
(creatinine 279μmol/l), CRP 436.4mg/l, and rhabdomyolysis
(creatinine kinase (CK) 12982U/l) with metabolic acidosis
(pH 7.26, PaO2 10.9 kPa, PaCO2 3.7 kPa, HCO3- 12.3mmol/l,
and BE -15mmol/l with lactate 2.8mmol/l). An urgent com-
puter tomography (CT) showed unspecific diffuse intestinal
dilatation without signs of perforation or free fluid. The lungs
presented only with dorsal right dystelectasis but revealed no
pulmonary infiltrations. Due to the rapid clinical deteriora-
tion, it was decided to take blood cultures, begin with antibi-
otics (piperacillin-tazobactam, clindamycin), and transfer
the patient to the intensive care unit with the diagnosis of
sepsis due to erysipelas of the left arm with suspected fasciitis.
On arrival at the intensive care unit, the patient was
increasingly agitated and an intravenous therapy with dex-
medetomidine was initiated. To restore hemodynamic stabil-
ity, a combined therapy with fluids and noradrenalin was
started. Three liters of oxygen through a nasal cannula was
sufficient to achieve a good oxygenation of the lungs. How-
ever, there was a progressive distension of the abdomen
and a clinical deterioration with no clear focus of infection,
resulting in an exploratory laparotomy. Intraoperatively, a
puncture of the joints and tissue biopsies of the left arm
and hand were performed with negative results in the cul-
tures the following days. Intra-abdominally, there were mul-
tiple tissue adhesions with signs of low vascular perfusion,
but no signs of spontaneous intestinal perforation. Because
of an accidental colon injury and observed general low tissue
perfusion, it was decided to conduct a split colostomy. The
following days, the patient remained under mechanical
ventilation with hemodynamic instability and agitation.
Vasoactive drugs could be reduced, and lactate as well as
inflammatory parameters improved. A week after surgery,
the stoma was covered with a large quantity of filamentous
structures compatible with fungal colonization. After collect-
ing surface cultures, a local treatment with amphotericin B
was begun. The following day, the same growth was found
in the stoma. Simultaneously, the clinical status rapidly
declined with an increase of inflammation parameters and a
new deterioration of renal function, which required an
increase of vasoactive drugs. Since the patient had an advance
directive limiting therapeutic measures in the case of severe
illness or need of renal substitution, a joint decision with the
family was taken to initiate comfort therapy. The patient died
a few hours later, after a week spent in the intensive care unit.
The microbiologic culture showed the presence of Asper-
gillus fumigatus in the stoma. Because of a fulminant infec-
tious process with unknown focus, the permission to
perform an autopsy was obtained from the family. Postmor-
tem investigation showed multiple gastric and intestinal
ulcerative lesions with evidence of an invasive fungal infec-
tion. Fungi could be detected within the mucosa and mucosal
and submucosal vessels. By morphology and also confirmed
by molecular pathology, the presence of Aspergillus
Figure 1: Hematoxylin-eosin staining of ulcers of the small intestine with intravascular aspergillus manifestation (4x magnification).
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fumigatus was confirmed (Figures 1–3). The presence of fungi
could also be demonstrated in the lungs, in particular the alve-
oli of the right lower lobe; however, it was without signs of
invasion (Figure 4). The biopsies of the left arm showed a
phlegmonous inflammation without mycotic presence.
3. Discussion and Conclusions
The diagnosis of a fungal infection keeps being a challenge:
the symptoms of gastrointestinal aspergillosis, such as
abdominal pain, diarrhea, hemorrhage, and possibly intesti-
nal obstruction with perforation, are nonspecific, so a high
clinical suspicion is needed to consider testing for aspergillo-
sis (for example, by testing for antigens like galactomannan
[6] and beta (1, 3)-D-glucan [7]). One of the most extensive
descriptions of invasive aspergillosis is the work of Eggimann
et al. [2]. Their review of gastrointestinal aspergillosis reports
only immunocompromised patients; most of them were dis-
seminated but extremely rarely caused by isolated gut asper-
gillosis (8%). The authors propose to consider not only an air
portal entry but also a gastrointestinal portal entry for inva-
sive Aspergillosis spp. They postulate that aspergillus spores
can find favorable conditions to reproduce in the ulcers on
the mucous surface of the digestive tract. In our case, at
postmortem diagnostics, we found aspergillus in the alve-
oli and trachea, but could not prove pulmonary invasion
histologically despite extensive tissue sampling. We therefore
interpret their occurrence as secondary (possibly due to
aspiration). The partial colectomy specimen submitted after
the intraoperative injury showed ischemic mucosal injury,
but no fungi could be objectified even after the second review.
Still, a contamination during surgical intervention and
Figure 3: Hematoxylin-eosin staining of the stomach with submucosal aspergillus (20x magnification).
Figure 2: Higher magnification (20x) of marked area in the image.
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accidental perforation cannot be excluded. In contrast, the
patient came to the hospital with gastrointestinal symptoms
and a long history of abdominal pain. It seems plausible that
the ulcerative mucosal lesions caused by a general ischemic
status throughout the entire intestinal tract provided the base
for mycotic invasion, in line with Eggimann’s hypothesis. To
the best of our knowledge, this constellation of primary gas-
trointestinal aspergillosis in an immunocompetent patient
without risk factors has been described in only a handful of
articles in the literature so far [3]. The retrospective study
of Kazan et al. [8] analyzes the presence of gut aspergillosis
in 21 patients with leukemia and allogenic hematopoietic
stem cell transplant. They describe poorly specific symptoms
like a prolonged history of abdominal pain, diarrhea, hemor-
rhage, and intestinal occlusion or perforation. In some cases,
a diagnosis was obtained through endoscopy and biopsy with
similar findings to ours. Eight patients presented with iso-
lated gastrointestinal aspergillosis which postulates an oral
portal of entry due to the ingestion of contaminated food.
In this series, the reported mortality was 57% and an optimal
therapy (surgery, antifungals, or combined) could not be
established. In the same line, the review of Reischies and
Hoenigl investigates the role of surgery as adjunctive option
to antifungal therapy in different manifestations of invasive
aspergillosis [9]. Despite all current therapeutic options, the
mortality rate of this opportunistic infection remains high
as described by Denning [10].
Our report illustrates the case of an immunocompetent
patient that developed a very rare entity which led to her
death. These findings led us to the conclusion that aspergillo-
sis infection should not be underestimated in the differential
diagnosis, even in immunocompetent patients.
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